4Telethon Kids Institute, Perth, WA, Australia.3Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.2School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.1National Centre for Asbestos Related Diseases, Institute of Respiratory Health, University of Western Australia, Perth, WA, Australia.Nowak 1,6, Willem Joost Lesterhuis 1,2,4, Richard A. Joel Kidman 1,2, Nicola Principe 1,2, Mark Watson 3, Timo Lassmann 4, Robert A. Clonal Diversity of Memory CD8 + T Cell Subsets Might Offer a Dynamic Biomarker of ICT Response.Moving Beyond Diversity: Novel Approaches to Study TCR Repertoires.Improving How TCR Repertoire Data is Represented.Expansion of Intra-Tumoral TCR Clonotypes is a Feature of Response to Anti-PD-1 Therapy.Nuanced Analysis of PD-1 + Blood T Cells Might Offer a Biomarker to Response to PD-1/L1 Blockade.
Anti-CTLA-4 Drives Clonal Expansion of Tumor Infiltrating Lymphocytes.Anti-CTLA-4 Monotherapy Remodels the Blood TCR Repertoire.TCR Repertoires Can be Characterized by Different Metrics.Sequencing Technology Is Important for the Characterization of TCR Repertoires.Measurements of Dynamic Change in the Immune System Could Offer a Biomarker of ICT Response.ICT is a Revolutionary Cancer Therapy, but Not All Patients Respond.The editor and reviewer's affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review. Jude Children's Research Hospital, United States
0 kommentar(er)
